KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Notes Payables (2016 - 2021)

Biocryst Pharmaceuticals filings provide 8 years of Notes Payables readings, the most recent being $30.0 million for Q3 2021.

  • On a quarterly basis, Notes Payables changed 0.37% to $30.0 million in Q3 2021 year-over-year; TTM through Sep 2021 was $30.0 million, a 0.37% change, with the full-year FY2020 number at $30.0 million, up 1.49% from a year prior.
  • Notes Payables hit $30.0 million in Q3 2021 for Biocryst Pharmaceuticals, roughly flat from $30.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $30.0 million in Q4 2020 to a low of $28.4 million in Q1 2017.
  • Median Notes Payables over the past 5 years was $29.3 million (2019), compared with a mean of $29.3 million.
  • Biggest five-year swings in Notes Payables: rose 1.57% in 2017 and later increased 0.37% in 2021.
  • Biocryst Pharmaceuticals' Notes Payables stood at $28.7 million in 2017, then increased by 1.53% to $29.1 million in 2018, then grew by 1.51% to $29.6 million in 2019, then grew by 1.49% to $30.0 million in 2020, then changed by 0.0% to $30.0 million in 2021.
  • The last three reported values for Notes Payables were $30.0 million (Q3 2021), $30.0 million (Q2 2021), and $30.0 million (Q1 2021) per Business Quant data.